Intrauterine G-CSF Administration in RIF

• Status: Completed
• Trial end date: 2018-12-20
• Target enrollment: 0
• Participant gender: Female

Summary

Aim of this study is to investigate the effects of intrauterine G-CSF on endometrial thickness, clinical pregnancy rate and live birth rate in a recurrent implantation failure (RIF) group

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gurgan Clinic
• Treatments: Lenograstim

Criteria

Inclusion Criteria:

• Women under the age of 40 who met the RIF definition

• Follicle-stimulating hormone (FSH) levels were <15 IU/mL

Exclusion Criteria:

• Patients with congenital uterine anomalies

• Patients with Asherman's syndrome

• Patients with uterine cavity distorted by myoma or endometrial polyps

• Patients with confirmed endometriosis or endometrioma

• Patients for whom G-CSF was contraindicated (active infections, kidney disease, sickle cell anemia, malignancies, chronic neutropenia)